other material
confidence high
sentiment negative
materiality 0.75
Eloxx Phase 2 ELX-02 CF trial misses efficacy endpoints; lung exposure low
Eloxx Pharmaceuticals, Inc.
- Combination of ELX-02 with ivacaftor did not achieve statistical significance for changes in SCC or FEV1.
- ELX-02 was well tolerated; no treatment-related serious adverse events reported.
- Evidence of activity seen in patients with higher baseline sweat chloride (p=0.00013 at Day 35).
- Steady-state lung drug levels averaged 2 µM, only 20% of lowest preclinical active concentration.
- Company plans to start proof-of-concept trial for ELX-02 in Alport syndrome later in 2022.